Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Expression of Connexin 43 and E-cadherin Protein and mRNA in Non-small Cell Lung Cancers in Chinese Patients

  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Aim: Connexin 43 (Cx43) and E-cadherin are important biomarkers related with cancer. Their expression at protein and mRNA levels was here investigated in 50 primary lung carcinoma tissues and 20 samples of adjacent normal tissue of Chinese patients with non-small cell lung cancer (NSCLC). Methods: Protein and mRNA expression were evaluated by ABC immunohistochemistry and RT-PCR. Results: (1) The positive expression rates of Cx43 and E-cadherin protein were higher in the adjacent normal tissues than those in the primary lung carcinoma tissues; (2) the positive expression rates of Cx43 and E-cadherin protein decreased with NSCLC progression; (3) the expression of E-cadherin protein was not related with the pathological type of NSCLC; and (4) the relative quantity of the Cx43 or E-cadherin mRNA expression was correlated with the the histological type, clinical stage, cancer cell differentiation and the lymph node metastasis. Conclusion: The data suggested that the Cx43 and E-cadherin are reduced with NSCLC progression, and might be important biomarkers for judging the metastasis and prognosis.

Keywords

References

  1. Brehm R, Ruttinger C, Fischer P, et al (2006). Transition from preinvasive carcinoma in situ to seminoma is accompanied by a reduction of connexin 43 expression in Sertoli cells and germ cells. Neoplasia, 8, 499-509. https://doi.org/10.1593/neo.05847
  2. Chen JT, Cheng YW, Chou MC, et al (2003). The correlation between aberrant connexin 43 mRNA expression induced by promoter methylation and nodal micrometastasis in non-small cell lung cancer. Clin Cancer Res, 9, 4200-4.
  3. Chen XF, Zhang HT, Qi QY, et al (2005). Expression of E-cadherin and nm23 is associated with the clinicopathological factors of human non-small cell lung cancer in China. Lung Cancer, 48, 69-76. https://doi.org/10.1016/j.lungcan.2004.09.009
  4. Cronier L, Crespin S, Strale PO, et al (2009). Gap Junctions and Cancer: New Functions for an Old Story. Antioxid Redox Signal, 11, 323-38. https://doi.org/10.1089/ars.2008.2153
  5. Dittmar T, Heyder C, Gloria-Maercker E, et al (2007). Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin Exper Metastasis, 25, 11-32.
  6. Fujimoto K, Nagafuchi A, Tsukita S, et al (1997). Dynamics of connexins, E-cadherin and alpha-catenin on cell membranes during gap junction formation. J Cell Sci, 110, 311-22.
  7. Hattori Y, Fukushima M, Maitani Y (2007). Non-viral delivery of the connexin43 gene with histone deacetylase inhibitor to human nasopharyngeal tumor c ells enhances gene expressi on and inhibits in vivo tumor growth. Int J Oncol, 30, 1427-39.
  8. Huang RP, Hossain MZ, Sehgal A, et al (1999). Reduced connexin43 expression in hig- grade human brain glioma cells. Surg Oncol, 70, 21-4. https://doi.org/10.1002/(SICI)1096-9098(199901)70:1<21::AID-JSO4>3.0.CO;2-0
  9. Jeanes A, Gottardi CJ, Yap AS (2008). Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene, 27, 6920-9. https://doi.org/10.1038/onc.2008.343
  10. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  11. Jinn Y, Ichioka M, Marumo F (1998). Expression of connexin32 and connexin43 gap junction proteins and E- cadherin in human lung cancer. Cancer Lett, 127, 161- 9. https://doi.org/10.1016/S0304-3835(98)00032-9
  12. Jinn Y, Inase N (2010). Connexin43, E-Cadherin, $\beta$-Catenin and ZO-1 Expression, and Aberrant Methylation of the Connexin43 Gene in NSCLC. Anticancer Res, 30, 2271-8.
  13. Jongen WM, Fitzgerald DJ, Asamoto M, et al (1991). Regulation of connexin 43-mediated gap junctional intercellular communication by $Ca^{2+}$ in mouse epidermal cells is controlled by E-cadherin. J Cell Biol, 114, 545-55. https://doi.org/10.1083/jcb.114.3.545
  14. Kato Y, Hirano T, Yoshida K, et al (2005). Frequent loss of E-cadherin and/or catenins in intrabronchial lesions during carcinogenesis of the bronchial epithelium. Lung Cancer, 48, 323-30. https://doi.org/10.1016/j.lungcan.2004.11.012
  15. King TJ, Bertram JS (2005). Connexins as targets for cancer chemoprevention and chemotherapy. Biochim Biophys Acta, 1719, 146-60. https://doi.org/10.1016/j.bbamem.2005.08.012
  16. Kobayashi H, Boelte KC, Lin PC (2007). Endothelial Cell Adhesion Molecules and Cancer Progression. Curr Med Chem, 14, 377-86. https://doi.org/10.2174/092986707779941032
  17. Laird DW (2006). Life cycle of connexins in health and disease. J Biochem, 394, 527-43. https://doi.org/10.1042/BJ20051922
  18. Laird DW, Fistouris P, Batist G, et al (1999). Deficiency of connexin43 gap junction is an independent marker for breast tumors. Cancer Res, 59, 4101-10.
  19. Langlois S, Cowan KN, Shao Q, et al (2010). The tumor-suppressive function of connexin43 in keratinocytes is mediated in part via interaction with caveolin-1. Cancer Res, 70, 4222-32. https://doi.org/10.1158/0008-5472.CAN-09-3281
  20. Losa D, Chanson M, Crespin S (2011). Connexins as therapeutic targets in lung disease. Expert Opin Ther Targets, 15, 989-1002. https://doi.org/10.1517/14728222.2011.584875
  21. Makrilia N, Kollias A, Manolopoulos L, et al (2009). Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest, 27, 1023-37. https://doi.org/10.3109/07357900902769749
  22. McLachlan E, Shao Q, Wang HL, et al (2006). Connexins act as tumor suppressors in three-dimensional mammary cell organoids by regulating differentiation and angiogenesis. Cancer Res, 66, 9886-94. https://doi.org/10.1158/0008-5472.CAN-05-4302
  23. Mesnil M, Crespin S, Avanzo JL, et al (2005). Defective gap junctional intercellular communication in the carcinogenic process. Biochim Biophys Acta, 1719, 125-45. https://doi.org/10.1016/j.bbamem.2005.11.004
  24. Murray SA, Davis K, Fishman LM, et al (2000). Alpha connexin43 gapjunction are decreased in human adrenocortical tumors. J Clin Endocrinol Metab, 85, 890-5. https://doi.org/10.1210/jc.85.2.890
  25. Musil B, Linda S, Gerald M, et al (1990). Differential phosphorylation of gap junction protein connexin43 in junctional communication- competent and different cell lines. J Cell Biol, 111, 20777-9.
  26. Naus CC, Laird DW (2010). Implications and challenges of connexin connections to cancer. Nat Rev Cancer, 10, 435-41. https://doi.org/10.1038/nrc2841
  27. Ogawa K, Pitchakarn P, Suzuki S, et al (2012). Silencing of connexin 43 suppresses invasion, migration and lung metastasis of rat hepatocellular carcinoma cells. Cancer Sci, 103, 860-7. https://doi.org/10.1111/j.1349-7006.2012.02228.x
  28. Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43. https://doi.org/10.1016/S1470-2045(01)00486-7
  29. Pertz O, Bozic D, Koch AW, et al (1999). A new crystal structure, $Ca^{2+}$dependence and mutational analysis reveal molecular details of E-cadherin homoassociation. EMBO J, 18, 1738-47. https://doi.org/10.1093/emboj/18.7.1738
  30. Plante I, Stewart MK, Barr K, et al (2011). Cx43 suppresses mammary tumor metastasis to the lung in a Cx43 mutant mouse model of human disease. Oncogene, 30, 1681-92. https://doi.org/10.1038/onc.2010.551
  31. Proksch E, Brandner JM, Jensen JM (2008). The skin: an indispensable barrier. Exper Dermatol, 17, 1063-72. https://doi.org/10.1111/j.1600-0625.2008.00786.x
  32. Smythe W, Williams J, Wheelock M, et al (1999). Cadherin and catenin expression in normal bronchial epithelium and non- small cell lung cancer. Lung Cancer, 24, 157-68. https://doi.org/10.1016/S0169-5002(99)00032-X
  33. Sohl G, Willecke K (2004). Gap junctions and the connexin protein family. Cardiovasc Res, 62, 228-32. https://doi.org/10.1016/j.cardiores.2003.11.013
  34. Solan JL, Lampe PD (2009). Connexin43 phosphorylation-structural changes and biological effects. J Biochem, 419, 261-72. https://doi.org/10.1042/BJ20082319
  35. Tomai E, Brownell HL, Tufescu TV, et al (1999). Gap junctional intercellular communication in cultured human lung carcinoma cells. Lung Cancer, 23, 223-31. https://doi.org/10.1016/S0169-5002(99)00016-1
  36. Wheelock MJ, Shintani Y, Maeda M, et al (2008). Cadherin switching. J Cell Sci, 121, 727-735. https://doi.org/10.1242/jcs.000455
  37. Xu HT, Li QC, Zhang YX, et al (2008). Connexin 43 recruits E-cadherin expression and inhibits the malignant behaviour of lung cancer cells. Folia Histochem Cytobiol, 46, 315-21.
  38. Yamasaki H, Krutovskikh V, Mesnil M, et al (1999). Role of connexin (gap junction) genes in cell growth control and carcinogenesis. CR Acad Sci III, 322, 151-9. https://doi.org/10.1016/S0764-4469(99)80038-9

Cited by

  1. Pathological Implications of Cx43 Down-regulation in Human Colon Cancer vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.2987
  2. Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer vol.31, pp.6, 2014, https://doi.org/10.3892/or.2014.3129
  3. Prognostic and Clinicopathological Significance of Downregulated E-Cadherin Expression in Patients with Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis vol.9, pp.6, 2014, https://doi.org/10.1371/journal.pone.0099763
  4. Connexin43 Suppresses Lung Cancer Stem Cells vol.11, pp.2, 2019, https://doi.org/10.3390/cancers11020175